Extended follow-up data from the phase III monarchE trial showed that adding the CDK inhibitor abemaciclib to standard adjuvant endocrine therapy continued to improve invasive disease-free survival among patients with high-risk, node-positive, early-stage, HR-positive, HER2-negative breast cancer.